Symbol | Exchange | Currency | |||
|---|---|---|---|---|---|
| JNJ | · | NYSE | · | USD | |
| JNJ | · | CBOE Canada | · | CAD | |
| JNJ | · | Toronto | · | CAD | |
| JNJ | · | Mexico | · | MXN | |
| 1JNJ | · | Milan | · | EUR | |
| JNJ | · | Switzerland | · | CHF | |
| JNJ | · | Frankfurt | · | EUR | |
| JNJ | · | Xetra | · | EUR | |
| JNJ | · | TradeGate | · | EUR | |
| JNJm | · | Buenos Aires | · | ARS | |
| DJNJ3m | · | Buenos Aires | · | ARS | |
| DJNJ2m | · | Buenos Aires | · | ARS | |
| JNJB34 | · | B3 | · | BRL | |
| JNJ | · | Vienna | · | EUR | |
| JNJ | · | Ukraine | · | UAH | |
| JNJ_KZ | · | KASE | · | USD | |
| JNJ | · | Colombia | · | COP | |
| JNJ | · | Lima | · | USD |
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Oncology Powerhouse | Johnson & Johnson's oncology division emerges as a key growth driver, with CARVYKTI leading the charge and projections of $50 billion in oncology sales by 2030 |
Financial Resilience | Despite challenges, J&J reports robust Q4 2024 results with 5.9% adjusted operational sales growth, surpassing expectations and demonstrating financial stability |
Strategic Expansion | J&J explores CAR-T therapies beyond oncology, venturing into autoimmune diseases and strengthening its portfolio through strategic acquisitions like V-Wave |
Analyst Perspectives | Price targets range from $152 to $215, reflecting varied outlooks on J&J's growth potential amid ongoing talc litigation and upcoming Stelara biosimilar competition |
Metrics to compare | JNJ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJNJPeersSector | |
|---|---|---|---|---|
P/E Ratio | 21.9x | 22.4x | −0.5x | |
PEG Ratio | 0.24 | 0.40 | 0.00 | |
Price/Book | 7.2x | 7.5x | 2.6x | |
Price / LTM Sales | 6.2x | 4.8x | 3.3x | |
Upside (Analyst Target) | −2.6% | 0.0% | 47.0% | |
Fair Value Upside | Unlock | 6.5% | 5.9% | Unlock |